FLT3 and acute myeloid leukemia: In a subsequent phase II trial that included old, unfit, and previously untreated AML patients with either mutated or wild-type FLT3, lestaurtinib treatment as a single agent for 8 weeks led to non-sustained reduction in blasts [28].